Response to peginterferon treatment in hepatitis C virus-associated splenic lymphoma with villous lymphocytes.
Kanbay
Mehmet
M
Selcuk
Haldun
H
Gur
Gurden
G
Dagli
Neslihan
N
Karakus
Sema
S
Yilmaz
Ugur
U
D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003593:Cytoplasm / Q000648:ultrastructure; D016174:Hepacivirus; D006526:Hepatitis C / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008214:Lymphocytes / Q000097:blood / Q000648:ultrastructure; D016393:Lymphoma, B-Cell / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000821:virology; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D015995:Prevalence; D011994:Recombinant Proteins; D012074:Remission Induction / Q000379:methods; D013160:Splenic Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b